Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Alzheimer's Disease Health Center

Font Size

New Steps Toward Stopping Alzheimer’s

Results Still to Come for a Highly Watched Drug
WebMD Health News
Reviewed by Louise Chang, MD

June 11, 2007 - Scientists reported some progress in their search for new drugs to treat Alzheimer’s disease Monday, even while researchers studying a closely watched new drug said they must rework their data to determine if it is effective.

Researchers attending a major scientific meeting in Washington have not achieved any “magic bullets” against the brain-wasting effects of Alzheimer’s disease. At the same time, they say they’re optimistic that a series of new treatments could prove to slow or reverse the disease.

Scientists studying one promising new drug, called Alzhemed, had hoped to announce major new findings this week. But the study leader announced that statistical issues would force scientist to reanalyze their results before determining if the drug works.

Reworking of data is often a red flag for regulators approving new drugs because it can be a sign the product did not work as hoped under a company’s original study design. But researcher Paul Aisen, MD, insisted at the annual meeting of the Alzheimer’s Association that the move was part of the overall study plan.

“This process does not indicate that the drug didn’t work,” said Aisen, a professor of neurology at Georgetown University, who is leading the Alzhemed study for Neurochem Inc.

The drug works in theory by blocking the formation of amyloid, an inflammation-causing protein known to be a key cause Alzheimer’s disease.

Aisen suggested that some early data were “in favor of treatment” instead of placebo pills, but he said he would not speculate further on whether the drug appears effective.

“At this point, conclusions can’t be drawn,” he said.

If the drug proves worthy, it could be a major step in Alzheimer’s treatment. Existing drugs on the market mostly slow the disease’s unrelenting progression or ease some symptoms. Observers eagerly await Alzhemed’s results because it could actually be a breakthrough in treating the underlying disease itself.

But for now, that breakthrough remains unproven.

Sam Gandy, MD, who leads the Alzheimer’s Association scientific advisory council, called the delay “science as usual.”

“This is exactly what we should expect: incremental progress,” said Sam Gandy, “We don’t expect there to be one single compound” that will prove to be a cure for the disease.

Today on WebMD

Remember your finger
When it’s more than just forgetfulness.
senior man with serious expression
Which kinds are treatable?
senior man
Common symptoms to look for.
mri scan of human brain
Can drinking red wine reverse the disease?
eating blueberries
Colored mri of brain
Close up of elderly couple holding hands
mature woman
Woman comforting ailing mother
Senior woman with serious expression